Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership with Beijing Highthink Pharmaceutical Technology Service Co., Ltd. The collaboration is aimed at providing Contract Research Organization (CRO) services, specifically to support a clinical study for Apeloa’s generic version of semaglutide.
Under the terms of the agreement, the two companies will collaborate on various aspects of the clinical trial, including comparative analysis, efficacy and safety evaluation, and clinical trial design. Financial details of the partnership have not been disclosed.- Flcube.com
